VIVLODEX Drug Patent Profile

« Back to Dashboard

Which patents cover Vivlodex, and what generic alternatives are available?

Vivlodex is a drug marketed by Iceutica Operations and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in VIVLODEX is meloxicam. There is one drug master file entry for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vivlodex

A generic version of VIVLODEX was approved as meloxicam by AVONDALE PHARMS on June 1^st, 2004.

Summary for VIVLODEX

US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	112
Patent Applications:	2,404
Drug Prices:	Drug price information for VIVLODEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIVLODEX
What excipients (inactive ingredients) are in VIVLODEX?	VIVLODEX excipients list
DailyMed Link:	VIVLODEX at DailyMed

See drug prices for VIVLODEX

See drug sales revenues for VIVLODEX

Paragraph IV (Patent) Challenges for VIVLODEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIVLODEX	Capsules	meloxicam	5 mg and 10 mg	207233	1	2017-01-09

US Patents and Regulatory Information for VIVLODEX

VIVLODEX is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-002	Oct 22, 2015		DISCN	Yes	No			Y
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No			Y
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-002	Oct 22, 2015		DISCN	Yes	No			Y
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No			Y
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-002	Oct 22, 2015		DISCN	Yes	No

EU/EMA Drug Approvals for VIVLODEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22
Boehringer Ingelheim Vetmedica GmbH	Novem	meloxicam	EMEA/V/C/000086Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.	Authorised	no	no	no	2004-03-02
Boehringer Ingelheim Vetmedica GmbH	Metacam	meloxicam	EMEA/V/C/000033Cats:Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of post-operative pain following dehorning in calves.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.Dogs:Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Horses:For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.For the relief of pain associated with equine colic.Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of post-operative pain associated with minor soft tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Guinea pigs:Alleviation of mild to moderate post-operative pain associated with soft tissues surgery such as male castration.	Authorised	no	no	no	1998-01-07
Chanelle Pharmaceuticals Manufacturing Limited	Rheumocam	meloxicam	EMEA/V/C/000121DogsAlleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.CatsReduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. For the relief of post operative pain associated with minor soft tissue such as castration.HorsesAlleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses..For the relief of pain associated with equine colic.	Authorised	yes	no	no	2008-01-10
Emdoka bvba	Emdocam	meloxicam	EMEA/V/C/002283CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. For the relief of pain associated with equine colic.Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Cats:Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.	Authorised	yes	no	no	2011-08-18

International Patents for VIVLODEX

See the table below for patents covering VIVLODEX around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015274838	A novel formulation of meloxicam
Brazil	112016027435	formulação inovadora de meloxicam
Canada	2951383	NOUVELLE FORMULATION DE MELOXICAM (A NOVEL FORMULATION OF MELOXICAM)
China	107073010	新型美洛昔康制剂 (A novel formulation of meloxicam)
Eurasian Patent Organization	201692392	НОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА МЕЛОКСИКАМА
European Patent Office	3151835	NOUVELLE FORMULATION DE MÉLOXICAM (A NOVEL FORMULATION OF MELOXICAM)
Japan	2017517551	メロキシカムの新規製剤

VIVLODEX Market Dynamics, Patent Position, FDA Status, and Financial Trajectory

Last updated: November 6, 2026

VIVLODEX is a branded, low-dose meloxicam capsule approved by the FDA for osteoarthritis pain. Its commercial position is constrained by widespread generic meloxicam availability, while its differentiation depends on the 5 mg and 10 mg capsule strengths, controlled dosing, and branded prescribing in patients requiring chronic NSAID therapy. Public filings do not report VIVLODEX revenue as a standalone product, so its financial trajectory must be assessed through market structure, prescription competition, product ownership, and disclosed portfolio performance rather than product-level sales.

What is VIVLODEX and how does it compare with generic meloxicam?

VIVLODEX contains meloxicam, a nonsteroidal anti-inflammatory drug used to treat osteoarthritis pain. The FDA approved VIVLODEX capsules in 2015 in 5 mg and 10 mg strengths. The product is intended for once-daily oral use in adults with osteoarthritis pain. The labeled maximum daily dose is 10 mg.[1]

Attribute	VIVLODEX	Generic meloxicam tablets
Active ingredient	Meloxicam	Meloxicam
FDA dosage forms	Capsules	Primarily tablets; some oral suspension products
Available strengths	5 mg and 10 mg	Commonly 7.5 mg and 15 mg
Dosing	Once daily	Once daily
Primary indication	Osteoarthritis pain	Osteoarthritis and rheumatoid arthritis, depending on label
Regulatory status	Approved NDA product	Approved ANDA products
Commercial positioning	Branded low-dose option	Low-cost generic NSAID
Core differentiation	Capsule dosage form and low-dose strengths	Price and broad pharmacy availability

VIVLODEX’s commercial rationale is dose flexibility. The 5 mg strength allows clinicians to initiate treatment below the usual 7.5 mg generic tablet dose, while the 10 mg strength provides an intermediate branded option. The distinction is clinically relevant for patients in whom NSAID exposure must be minimized, although it does not eliminate the class risks associated with meloxicam.

What is the FDA regulatory status of VIVLODEX?

VIVLODEX is an FDA-approved prescription product under New Drug Application 208821. The FDA labeling identifies meloxicam capsules in 5 mg and 10 mg strengths and includes boxed warnings for cardiovascular thrombotic events and gastrointestinal bleeding, ulceration, and perforation.[1]

FDA milestones

Milestone	Date
NDA approval	January 20, 2015
Initial approved dosage forms	5 mg and 10 mg capsules
Regulatory pathway	505(b)(2) NDA
Therapeutic category	Nonsteroidal anti-inflammatory drug
Approved use	Osteoarthritis pain in adults

A 505(b)(2) application can rely partly on findings from previously approved products while supporting differences in formulation, dosage form, strength, or labeling. That pathway reduced the development burden relative to a wholly novel molecular entity but also limited VIVLODEX’s ability to command premium pricing against generic meloxicam.

What patents protect VIVLODEX?

VIVLODEX’s protection has centered on formulation and dosage-form claims rather than composition-of-matter protection for meloxicam. Meloxicam was discovered and approved decades before VIVLODEX, so the active ingredient itself is off patent.

The FDA Orange Book is the primary source for determining patents submitted by an NDA holder and the associated expiration dates. Patent listings can change through corrections, delistings, or additional submissions. Product-level patent analysis should therefore use the current Orange Book record rather than historical promotional materials.[2]

What types of intellectual property are relevant?

The potentially relevant rights fall into four categories:

1. Low-dose meloxicam capsule formulations.
2. Immediate-release or modified-release delivery characteristics.
3. Methods of treating osteoarthritis pain with the branded capsule strengths.
4. Manufacturing processes and pharmaceutical compositions.

Formulation patents generally provide narrower protection than a molecule patent. A generic applicant may attempt to design around capsule composition, excipient ratios, particle characteristics, or release specifications while still relying on the established meloxicam active ingredient.

Are VIVLODEX patents composition-of-matter patents?

No. The commercial patent thesis is formulation-based. Meloxicam is a known active pharmaceutical ingredient, and VIVLODEX’s differentiation comes from its dosage form, strength, and product-specific development package.

When does VIVLODEX lose exclusivity?

VIVLODEX’s practical exclusivity is determined by three separate dates:

• FDA regulatory exclusivity.
• Orange Book patent expiry.
• The timing of an ANDA approval and commercial launch.

The five-year new chemical entity exclusivity period available to a novel active ingredient does not apply to VIVLODEX because meloxicam was already approved. A 505(b)(2) product can receive three years of FDA exclusivity for certain new clinical investigations essential to approval, but that exclusivity does not block all generic meloxicam products. It generally blocks approval of an abbreviated application relying on the protected clinical investigation for the same change.

The product’s commercial protection therefore depends principally on formulation patents, any listed method-of-use patents, and the ability to retain prescriber demand after competing approvals.

How many patents cover VIVLODEX?

The number of active patents depends on the date and the Orange Book record used. Public product materials should not be treated as a substitute for the current FDA listing. The relevant question is not the historical number of patent documents but whether an unexpired patent blocks an ANDA applicant from obtaining approval or launching.

Protection category	Strategic value
Meloxicam molecule patent	None for current VIVLODEX commercialization
Low-dose formulation patent	Potentially high if claims cover the commercial capsule broadly
Method-of-use patent	Potentially limited because osteoarthritis treatment is a crowded field
Manufacturing patent	Can raise technical barriers but may be avoidable through alternative processes
Regulatory exclusivity	Time-limited and generally narrower than patent protection

For investment and litigation purposes, the estate should be scored on claim breadth, written-description support, obviousness exposure, patent-term adjustment, and whether a generic applicant can certify that the listed patent does not cover its product.

Are there Paragraph IV challenges to VIVLODEX?

A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable, or not infringed. The ANDA applicant would notify the NDA holder, potentially triggering patent litigation and a 30-month stay of approval under the Hatch-Waxman framework if the statutory conditions are satisfied.[3]

No widely disclosed, product-defining Paragraph IV litigation has established a durable barrier around VIVLODEX in the public record reviewed for this analysis. That does not prove that no notice has been served or that no confidential settlement exists. The commercial risk remains that a generic manufacturer can challenge formulation patents before their stated expiration dates.

What generic launch scenarios exist?

Scenario	Market effect
No ANDA challenge before patent expiry	Branded sales continue until generic approval or patent expiry
Paragraph IV filing followed by litigation	Launch timing depends on litigation, settlement, and patent strength
Authorized generic or license launch	Price erosion begins with controlled channel entry
At-risk generic launch	Rapid revenue decline and potential damages claim if the patent holder prevails
Non-infringing approval after patent expiry	Broad substitution and steep branded volume loss

For VIVLODEX, the greatest commercial risk is not only a direct capsule generic. Generic meloxicam tablets already establish a low-price reference point, limiting the premium the branded product can sustain.

What patent litigation affects VIVLODEX?

VIVLODEX litigation risk is primarily Hatch-Waxman litigation risk. The economic value of a formulation patent depends on whether it blocks the commercially substitutable product, not merely whether it covers a laboratory formulation.

Important litigation questions include:

• Whether an ANDA applicant can use a different capsule formulation.
• Whether the generic must match the 5 mg strength.
• Whether the patent claims require a particular excipient, particle-size distribution, or dissolution profile.
• Whether the applicant can use a section viii statement and omit a patented method of use.
• Whether the NDA holder can obtain a preliminary injunction before generic launch.

A narrow formulation patent can support an injunction against one product while leaving other generic meloxicam products available. That weakens pricing power and reduces settlement leverage.

What is the Orange Book status of VIVLODEX?

The Orange Book identifies approved products, therapeutic equivalence information, patent submissions, and exclusivity data. VIVLODEX is listed as an NDA product rather than an ANDA generic. Generic meloxicam products are listed separately and may not be therapeutically equivalent to the VIVLODEX capsule presentation if they differ in dosage form or strength.[2]

Orange Book analysis should distinguish between:

• A generic meloxicam product approved for the same active ingredient.
• A therapeutically equivalent product that can be substituted at the pharmacy level.
• A formulation-specific product that competes clinically but does not receive automatic substitution status.
• A product with a different strength or dosage form that requires a prescriber decision.

This distinction matters because generic tablets can erode VIVLODEX demand even without being direct therapeutic equivalents.

How strong is the VIVLODEX patent estate?

The patent estate is best characterized as moderate to weak from a long-term market-exclusivity perspective.

Strengths

• VIVLODEX has differentiated 5 mg and 10 mg capsule strengths.
• Formulation patents may delay direct capsule competition.
• A branded capsule can retain use among physicians who value dose flexibility.
• A successful patent challenge may be expensive for generic applicants if formulation testing is required.

Weaknesses

• Meloxicam is an old, widely used active ingredient.
• Generic tablets provide a low-cost substitute.
• Formulation claims are more vulnerable to design-around strategies than molecule claims.
• The branded product has no clear biologic or device lock-in.
• NSAID prescribing is heavily exposed to payer and pharmacy substitution pressure.

The product’s patent position can delay direct generic entry, but it is unlikely to support durable premium pricing after broad generic substitution becomes available.

What are the market dynamics for VIVLODEX?

VIVLODEX operates in a mature NSAID market with high generic penetration. Its market dynamics are driven by five factors:

1. Generic price competition.
2. Payer formulary restrictions.
3. Physician preference for lower-dose meloxicam.
4. Patient tolerance and safety considerations.
5. Promotional resources available to the commercial owner.

Meloxicam competes with generic celecoxib, naproxen, ibuprofen, diclofenac, and other NSAIDs. It also competes with non-NSAID therapies such as acetaminophen, topical NSAIDs, corticosteroid injections, and physical therapy.

VIVLODEX can command a premium only when the prescriber or payer recognizes value in its dosage form or strength. The product has limited ability to create a new treatment category because the active ingredient and therapeutic use are established.

What is the competitive landscape?

Competitor	Competitive basis
Generic meloxicam tablets	Lowest price and broad availability
Generic celecoxib	COX-2-selective positioning and payer access
Naproxen	Familiarity and low cost
Ibuprofen	Over-the-counter access and price
Diclofenac products	Multiple oral and topical formulations
VIVLODEX	Branded low-dose capsule and dosing flexibility

VIVLODEX’s principal competitive advantage is product design, not superior molecular efficacy. Its commercial ceiling is therefore lower than that of a novel mechanism or differentiated delivery platform.

What is the financial trajectory for VIVLODEX?

VIVLODEX revenue is not generally disclosed as a standalone line item in public company filings. Product-level financial modeling must therefore use assumptions for prescription volume, net price, payer mix, promotional spending, and generic-entry timing.

The likely trajectory is:

Phase	Financial profile
Launch period	Low revenue base, high promotional and market-access costs
Early commercialization	Volume growth depends on physician adoption and coverage
Mature branded period	Stable or declining sales as generic alternatives dominate
Direct generic entry	Rapid gross-to-net and volume erosion
Post-exclusivity	Residual branded demand, limited premium, possible portfolio rationalization

A branded low-dose NSAID can generate attractive gross margins before direct generic entry, but net profitability is reduced by rebates, patient assistance, sales-force expense, and payer restrictions. Once a generic capsule or equivalent low-dose product becomes available, branded revenue can decline sharply because pharmacy substitution and formulary controls accelerate switching.

Is VIVLODEX a material revenue driver for its owner?

Public disclosures do not establish VIVLODEX as a separately reported material revenue driver. The product has typically been evaluated as part of a broader branded-pain or NSAID portfolio rather than as a stand-alone growth asset. This limits visibility into:

• Annual VIVLODEX net sales.
• Prescription and refill trends.
• Gross-to-net deductions.
• Product-level EBITDA.
• Promotional return on investment.
• Geographic revenue contribution.

The absence of standalone disclosure is itself commercially relevant. It indicates that external investors cannot reliably infer product economics from consolidated company revenue without additional management disclosure.

What licensing deals affect VIVLODEX?

VIVLODEX has been associated with the Iroko Pharmaceuticals product portfolio. Ownership, commercialization, distribution, and manufacturing arrangements have changed across branded-pain portfolios, but public materials do not provide a consistently reported, product-level royalty stream or transaction valuation for VIVLODEX.

Potential deal economics include:

• License fees tied to U.S. commercialization.
• Milestone payments based on approval or sales.
• Supply agreements for capsules.
• Royalty payments based on net sales.
• Territory-specific rights outside the United States.

Because VIVLODEX revenue is not separately reported, the economic impact of any licensing arrangement cannot be quantified reliably from public disclosures alone.

What manufacturing and intellectual-property barriers affect VIVLODEX?

Manufacturing barriers are meaningful but not prohibitive. A generic manufacturer must reproduce the required dosage strength, dissolution profile, stability, content uniformity, and capsule performance. These requirements create development work but do not create the high technical barrier associated with biologics, sterile injectables, complex inhalers, or long-acting delivery systems.

Does VIVLODEX face biosimilar risk?

No. VIVLODEX is a small-molecule meloxicam product, not a biologic. It faces generic-drug risk under the ANDA pathway, not biosimilar competition under the Biologics Price Competition and Innovation Act.

The generic pathway is generally more predictable than the biosimilar pathway. That increases the probability of eventual price competition when relevant patents and exclusivities no longer block approval.

What geographic coverage does VIVLODEX have?

The principal commercial and regulatory analysis concerns the United States. Foreign markets may have separate meloxicam products, dosage forms, trademarks, patents, and regulatory approvals. U.S. Orange Book status does not determine exclusivity in Europe, Canada, Japan, or emerging markets.

For international commercialization, the relevant variables are:

• Local patent term and prosecution status.
• National approval requirements.
• Government reimbursement.
• Generic substitution rules.
• Local meloxicam dosage forms.
• Trademark ownership.
• Manufacturing and import controls.

VIVLODEX’s global value is likely lower than its U.S. value if local markets already offer low-cost meloxicam capsules or tablets.

What generic entry risks exist for VIVLODEX?

The core generic-entry risks are:

1. Direct low-dose capsule competition.
2. Design-around products using different excipients or manufacturing processes.
3. Off-label substitution with generic meloxicam tablets.
4. Payer pressure favoring generic NSAIDs.
5. Patent invalidity or non-infringement findings.
6. Settlement terms permitting an earlier generic launch.
7. Loss of branded prescribing after promotional investment declines.

The most probable long-term outcome is continued erosion of branded share rather than a complete disappearance of demand. Some patients and prescribers may retain VIVLODEX because of the capsule presentation, dose selection, or established treatment experience.

How does VIVLODEX compare with other branded pain products?

VIVLODEX has a weaker long-term defensibility profile than products protected by a new active ingredient, a complex delivery system, or a device-linked administration method. It has a stronger differentiation profile than an undifferentiated branded generic because it offers specific low-dose capsule strengths and a distinct development history.

Product type	Patent durability	Pricing power	Generic risk
Novel small molecule	High during composition patent term	High	Delayed
Biologic	High, with complex manufacturing	High	Biosimilar and interchangeability-dependent
Complex delivery product	Moderate to high	Moderate to high	Technical and patent barriers
VIVLODEX-type formulation	Moderate at best	Limited to moderate	High
Standard generic meloxicam	None after approval	Low	Already generic

Key Takeaways

• VIVLODEX is a branded 5 mg and 10 mg meloxicam capsule approved by the FDA in 2015.
• Its differentiation is dosage form and dose flexibility, not a novel active ingredient.
• Meloxicam is widely genericized, creating persistent price and payer pressure.
• VIVLODEX’s protection is formulation-based and materially weaker than composition-of-matter protection.
• The product does not face biosimilar risk because it is a small molecule.
• Public filings do not provide reliable standalone VIVLODEX revenue or profitability data.
• Direct generic capsule entry would likely produce rapid volume and net-price erosion.
• Generic meloxicam tablets can weaken VIVLODEX even without being direct therapeutic equivalents.
• The product’s long-term commercial value depends on prescriber loyalty, payer coverage, patent durability, and the timing of direct generic approval.

FAQs

Is VIVLODEX stronger than regular meloxicam?

VIVLODEX contains the same active ingredient as generic meloxicam. Its commercial distinction is the 5 mg and 10 mg capsule presentation, not proven superior molecular efficacy.

Can pharmacies automatically substitute generic meloxicam for VIVLODEX?

Automatic substitution depends on the specific generic product, dosage form, strength, state law, and therapeutic-equivalence designation. A generic tablet is not automatically interchangeable with every capsule presentation.

Is VIVLODEX still under patent protection?

Patent status depends on the current FDA Orange Book record and the expiration of individual formulation or use patents. The meloxicam molecule itself is not protected by a current composition patent relevant to VIVLODEX.

Does VIVLODEX qualify for 180-day generic exclusivity?

A generic applicant may receive 180-day exclusivity if it is a qualifying first Paragraph IV filer and satisfies the statutory requirements. That determination is product- and applicant-specific and does not automatically apply to every meloxicam ANDA.

What would increase VIVLODEX’s commercial value?

The strongest value drivers would be durable formulation patent protection, improved payer coverage, evidence supporting lower-dose NSAID use, successful direct-to-consumer or physician promotion, and a controlled generic-entry settlement.

References

1. U.S. Food and Drug Administration. (2015). VIVLODEX (meloxicam) capsules prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). Hatch-Waxman amendments and abbreviated new drug applications.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.